Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

target="_new">http://www.nasdaq.com.

Fourth Quarter and Year End 2007 Financial Results

-- Net loss for the fourth quarter of 2007 was $8.7 million, or

$0.11 per share, compared with a net loss for the fourth quarter of

2006 of $4.4 million, or $0.07 per share. Net loss for the twelve

months ended December 31, 2007 was $23.9 million, or $0.32 per share,

compared with a net loss of $14.8 million, or $0.24 per share, for

the comparable period last year.

-- Revenues for the fourth quarter of 2007 were $1.3 million, compared

with $426,000 for the fourth quarter of 2006. Cumulase product sales

for the fourth quarter of 2007 were $70,000, compared with $105,000

for the fourth quarter of 2006. Revenues under collaborative

agreements for the fourth quarter of 2007 were $1.2 million, compared

with $311,000 for the fourth quarter of 2006. Revenues under

collaborative agreements in 2007 primarily consisted of the

amortization of upfront fees received from Baxter and Roche of

$588,000 and research and development reimbursements from Baxter and

Roche of $652,000.

-- Research and development expenses for the fourth quarter of 2007 were

$7.3 million, compared with $2.7 million for the fourth quarter of

2006, reflecting increased compensation expenses including

share-based compensation expenses, research and development spending

on our various pre-clinical and clinical programs, and manufacturing

costs associated with the manufacturing scale-up of the Company's

rHuPH20 enzyme.

-- Selling, general and administrative expenses for the fourth quarter

of 2007 were $3.9 million, compared with $2.4 million for the fourth

quarter of 2006, reflecting increases in compensation expenses

including
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... science and medical research in the field of growth  ... KGaA, Darmstadt, Germany , today announced ... (GGI) for 2014. The awards were announced during a ...
(Date:9/18/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Sodium ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... China Acetic Acid Industry" is a professional and ... and Global Acetic Acid Market. The report ...
(Date:9/18/2014)... On Tuesday, Secretary of Energy Ernest Moniz ... National Lab Day on the Hill. The event highlighted ... system. Durbin and Risch also formally launched the Senate ... the reach of the national labs as leaders in ... of our nation's most pressing challenges. , "The national ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... 7 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... Corporate Development of BioMarin, will present a company update at ... 14, 2009 at 10:40 a.m. CT. Interested parties may ... the investor section of the BioMarin website, www.BMRN.com ...
... deCODE genetics, Inc.,(Nasdaq: DCGN ) today announced that it ... release to be issued on Monday, May 11, after,the close ... a live webcast of,its conference call to discuss these results ... Daylight Time/ 12pm GMT/1pm British Summer,Time. , ...
... (NYSE: CVD ) announced that it has ... McCartney currently serves as chairman of the board of ... and supply chain solutions. He was formerly president ... multibillion dollar provider of information access technologies. He was ...
Cached Biology Technology:BioMarin to Present at the Baird Growth Stock Conference 2deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results 2Covance Elects John McCartney to Company's Board of Directors 2
(Date:9/17/2014)... A rare genetic disorder known as Jacobsen syndrome has ... investigation by researchers at San Diego State University and ... suggesting better treatment options for people with Jacobsen syndrome, ... underpinnings of autism., Jacobsen syndrome affects approximately 1 in ... It occurs in a person when there is a ...
(Date:9/17/2014)... and their environmental impact recently scored a major win. ... on the bags, and Governor Jerry Brown is expected ... not yielding without a fight, according to an article ... newsmagazine of the American Chemical Society. , Alexander Tullo, ... campaign logged its first small victory in 1990 when ...
(Date:9/17/2014)... at IMIM (Hospital del Mar Medical Research Institute) and ... published a study in eLife showing that ... the evolution of new proteins, some of which could ... produce proteins from the instructions found in an RNA ... RNA containing information for the synthesis of proteins, meaning ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Parts of genome without a known function may play a key role in the birth of new proteins 2
... BOSTONScientists at Dana-Farber Cancer Institute have found a way ... treatment of several major forms of cancer. The ... portion of this anti-death protein, called MCL-1, to make ... allowing standard cancer drugs to kill the tumor cells ...
... Facility (ALCF), located at the U.S. Department of Energy,s ... processor-hours of computations at a mind-boggling speed of over ... and engineers to conduct cutting-edge research in just weeks ... dedicated to enabling breakthrough science science that will ...
... having trouble getting a date, French researchers suggest that ... were more prepared to give their number to an ... according to research that appears today in the journal ... There,s plenty of research indicating that the media affects ...
Cached Biology News:Molecular discovery suggests new strategy to fight cancer drug resistance 2Molecular discovery suggests new strategy to fight cancer drug resistance 3Over two billion hours served 2Love ballad leaves women more open to a date 2
XPMC2H Immunogen: XPMC2H (NP_065118, 323 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
XEDAR Antibody...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
Biology Products: